C oronary vasoregulation, the control of coronary artery diameter and blood flow, is an important and complex physiological function in which the endothelium plays a key role.' Many chemical and mechanical stimuli affect numerous endothelial cell receptors, triggering multiple signal transduction mechanisms and resulting in the release of several local activators.2 The net effects on coronary artery diameter and blood flow often result from opposing direct smooth muscle and endothelium-mediated actions. Nitric oxide (NO) is thought to be the predominant local endothelium-dependent vasodilator.3 In this issue of Circulation, Lefroy et a14 report the effects of intracoronary infusion of N0-monomethyl-L-arginine (L-NMMA), a specific inhibitor of NO synthesis, in 12 normal subjects. In the basal state, L-NMMA reduced distal coronary artery diameter and coronary artery blood flow. As previously demonstrated,5 intracoronary acetylcholine increased distal arterial diameter and blood flow. After L-NMMA infusion, acetylcholine (10-`mol/L) did not increase diameter but did increase coronary blood flow. This study underscores the role of NO in the maintenance of basal arterial diameter and blood flow and, importantly, suggests that acetylcholine regulates resistance vessel diameter through a non-NO mechanism. Interpretation of clinical studies in this complex area requires an understanding of four key issues: differences in the control of arterial diameter and blood flow, stimulus concentration, site specificity, and presence of vascular disease.
receptor blocker, administered before serotonin infusion potentiates its vasodilatory effects in normal vessels and blocks its vasoconstrictive effects in abnormal vessels.813 In contrast, intracoronary acetylcholine does not reduce coronary blood flow even in the presence of intense epicardial vasoconstriction associated with abnormal endothelial function.67 These variations result from different direct smooth muscle versus endothelium-dependent receptor effects and possibly to the release of other compensatory activators. The paper by Lefroy et a14 suggests the possibility that the endothelium-mediated pattern of acetylcholine response may be a result of its release of different site-specific, local activators, i.e., NO in epicardial arteries and some other substance(s) in resistance vessels.
Site Specificity
Acetylcholine and serotonin alter distal more than proximal coronary artery diameter in the presence of both normal and abnormal endothelial function.6"2"3 Vascular responses in the peripheral circulation tend to be similar to those in the coronary arteries, but peripheral vascular responses may vary quantitatively. '4 In part, this may result from differences in basal vascular "tone," which may explain quantitatively different effects of L-NMMA in the brachial artery (see below).
Stimulus Concentration
As a result of the opposing direct smooth muscle and endothelium-dependent effects, net vasoactive stimulus action tends to be extremely concentration dependent. 5 Comparison With Other Studies NO synthesis inhibition (L-NMMA) has been reported to markedly increase coronary artery resistance in the isolated buffer-perfused rabbit heart21 compared with the mild increase observed in the study by Clinical Implications This and other studies of endothelial function underscore the potential importance of dynamic epicardial and resistance vessel dysfunction in the pathogenesis of myocardial ischemia, in addition to fixed atherosclerotic stenosis. Angina with normal coronary angiography may also be caused by abnormal endothelial function in some patients.19 Traditional coronary arteriography does not evaluate both epicardial and resistance vessel vasoregulation, which could lead to substantial discordance between perceived coronary anatomy and patient functional capacity. Recently, assessment of generalized endothelial vasoactivity has been proposed as a preclinical, noninvasive means for detecting coronary and other atherosclerosis. 25 The approach holds the promise of being able to detect coronary disease at a sufficiently early stage that risk factor modification may avert subsequent clinical sequelae. Confirmation of the findings of Lefroy et a14 would support the presence of a resistance vessel endothelium-mediated, non-NO pathway that might provide insight into additional mechanisms and pharmalogical interventions for myocardial ischemia.
